|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 四氮杂环十二烷四乙酸>> 市场分析报告 |
四氮杂环十二烷四乙酸市场分析报告 |
|
Tetraaza-12-crown-4-1,4,7,10-tetraacetic acid (CAS 60239-18-1) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Immunomedics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... indications. Yttrium Y 90 Clivatuzumab tetraxetan Program Yttrium Y 90 clivatuzumab tetraxetan or hPAM4 labeled with Y-90, is the ... Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035 ... 131-1095, TLX591 (177LU Rosopatamab Tetraxetan), Alphamedix (???PB-DOTAMTATE), 67CU-SAR ... Novartis, Lutetium-177 vipivotide tetraxetan (Pluvicto) targets Prostate-Specific ... 131-1095, TLX591 (177LU ROSOPATAMAB TETRAXETAN), ALPHAMEDIX (???PB-DOTAMTATE), 67CU-SAR ... Global Market Report of DOTA (CAS 60239-18-1) December 2024 Global Market Report of DOTA (CAS 60239-18-1) December 2024 Prostate Cancer Treatment Market Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), End Users (Hospitals, Clinics, and Others), and Geography ... Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treating adult patients ... Metastatic Castration-Resistant Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major metastatic castration-resistant prostate cancer markets are expected to exhibit a CAGR of 5.44% during 2024-2034. The metastatic castration-resistant prostate cancer market has been comprehensively analyzed in IMARC's new report titled " ... Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major metastatic prostate cancer markets are expected to exhibit a CAGR of 6.22% during 2024-2034. The metastatic prostate cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic Prostate Cancer Market: Epidemiology, ... |